Clinical trials: Plaque Psoriasis.
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD1 (NCT06586112)
- Testing
- Envudeucitinib, Apremilast
- Where
- 156 sites in United States, Australia and 8 more
- Volunteers
- 912 people
- Sponsor
- Alumis Inc
Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD2 (NCT06588738)
- Testing
- Envudeucitinib, Apremilast
- Where
- 124 sites in United States, Austria and 10 more
- Volunteers
- 862 people
- Sponsor
- Alumis Inc
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
- Trial name
- NCT07116967
- Testing
- Deucravacitinib, Ustekinumab
- Where
- 411 sites in United States, Argentina and 23 more
- Volunteers
- 3,040 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
- Trial name
- POETYK-PsO-Ped (NCT06979453)
- Testing
- Deucravacitinib
- Where
- 133 sites in United States, Argentina and 14 more
- Volunteers
- 366 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Trial name
- PROMPT (NCT05155098)
- Testing
- secukinumab
- Where
- 10 sites in Thailand
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
- Trial name
- NCT06088199
- Testing
- Apremilast
- Where
- 30 sites in United States
- Volunteers
- 51 people
- Sponsor
- Amgen
Plaque Psoriasis
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
- Trial name
- NCT07449702
- Testing
- ORKA-001
- Where
- 39 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Oruka Therapeutics, Inc.
Plaque Psoriasis
Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis
Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis
- Trial name
- NCT02462122
- Testing
- IDP-118 Lotion, IDP-118 Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 215 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment [IGA] score of 3 or 4).
- Trial name
- NCT02515097
- Testing
- IDP-122 Lotion, IDP-122 Vehicle Lotion
- Where
- 15 sites in United States
- Volunteers
- 213 people
- Sponsor
- Bausch Health Americas, Inc.
Moderate-to-severe Plaque Psoriasis
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
- Trial name
- NCT07879885
- Testing
- HS-20137
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hansoh BioMedical R&D Company
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Plaque Psoriasis
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07474792
- Testing
- ORKA-002
- Where
- 40 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine…
- Trial name
- SEC-HOPE (NCT07683065)
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.
- Trial name
- NCT05565560
- Testing
- Apremilast
- Where
- 29 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Amgen
Plaque Psoriasis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- DREAM (NCT07039110)
- Where
- 84 sites in Canada, Czechia and 6 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis, Nail Psoriasis
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
This is an open label trial in subjects ≥12 years of age and older with chronic plaque psoriasis and moderate to severe nail psoriasis.
- Trial name
- NCT07725822
- Testing
- Roflumilast 0.3% topical cream
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Modern Research Associates, PLLC
Plaque Psoriasis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult…
- Trial name
- NCT07024602
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited